TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC
Year: 2026
Type: article
Abstract: Both intrinsic and acquired resistance to poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as a formidable challenge in clinical practice. Here, we report that the transcription factor E-twenty-six (Ets)-related gene ( ERG ) was highly expressed in PARPi-resistant prostate cancer and was correlated with PARPi resistance in castration-resistant prostate cancer (CRPC) cells. ERG was posttranslationally modified by tripartite motif-containing 28 (TRIM28) as SUMOylation at lysine 389 (K389), which promotes DNA homologous recombination repair (HRR), thereby weakening the efficacy of PARPis. Mechanistically, the SUMOylation of ERG (K389) inhibited protein degradation mediated by the SPOP-mediated ubiquitin-proteasome pathway, thereby stabilizing the protein. Concurrently, this posttranslational modification increased HRR capacity by inhibiting 53BP1 expression, which in turn reduced PARPi sensitivity. Blockade of ERG K389 SUMOylation can effectively impair DNA repair efficacy and overcome PARPi resistance. These findings suggest that TRIM28-mediated ERG SUMOylation conveys resistance to PARPis by inhibiting 53BP1 expression; combined TRIM28/ERG targeting and PARPi therapy may improve outcomes for ERG-positive CRPC patients.
Source: Science Advances
Authors: Shiwei Liu(Data curation, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Zhe Hong(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft), Zhongyuan Wang(Investigation, Methodology), Yongqing Zhang(Investigation, Methodology), Chenye Jiang(Investigation, Methodology), Yuchen Jiang(Investigation, Methodology), Runkai Zhang(Investigation, Methodology), Zheng Liu(Formal analysis), Zhi Shang(Data curation, Investigation, Resources), Guowen Lin(Software), Zongyuan Hong(Data curation, Writing – review & editing), Bo Dai(Conceptualization, Funding acquisition, Supervision)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,500
Awards: G2612058191, G3023834764, G5262863014
OpenAlex ID: W7236047018
